Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America.
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America.
Gynecol Oncol. 2021 Jan;160(1):161-168. doi: 10.1016/j.ygyno.2020.10.012. Epub 2020 Oct 21.
Lynch syndrome is the most common cause of inherited endometrial cancer, attributable to germline pathogenic variants (PV) in mismatch repair (MMR) genes. Tumor microsatellite instability (MSI-high) and MMR IHC abnormalities are characteristics of Lynch syndrome. Double somatic MMR gene PV also cause MSI-high endometrial cancers. The aim of this study was to determine the relative frequency of Lynch syndrome and double somatic MMR PV.
341 endometrial cancer patients enrolled in the Ohio Colorectal Cancer Prevention Initiative at The Ohio State University Comprehensive Cancer Center from 1/1/13-12/31/16. All tumors underwent immunohistochemical (IHC) staining for the four MMR proteins, MSI testing, and MLH1 methylation testing if the tumor was MMR-deficient (dMMR). Germline genetic testing for Lynch syndrome was undertaken for all cases with dMMR tumors lacking MLH1 methylation. Tumor sequencing followed if a germline MMR gene PV was not identified.
Twenty-seven percent (91/341) of tumors were either MSI-high or had abnormal IHC indicating dMMR. As expected, most dMMR tumors had MLH1 methylation; (69, 75.8% of the dMMR cases; 20.2% of total). Among the 22 (6.5%) cases with dMMR not explained by methylation, 10 (2.9% of total) were found to have Lynch syndrome (6 MSH6, 3 MSH2, 1 PMS2). Double somatic MMR PV accounted for the remaining 12 dMMR cases (3.5% of total).
Since double somatic MMR gene PV are as common as Lynch syndrome among endometrial cancer patients, paired tumor and germline testing for patients with non-methylated dMMR tumor may be the most efficient approach for LS screening.
林奇综合征是遗传性子宫内膜癌最常见的病因,与错配修复(MMR)基因中的种系致病性变异(PV)有关。肿瘤微卫星不稳定性(MSI-高)和 MMR IHC 异常是林奇综合征的特征。双体细胞 MMR 基因 PV 也会导致 MSI-高的子宫内膜癌。本研究旨在确定林奇综合征和双体细胞 MMR PV 的相对频率。
2013 年 1 月 1 日至 2016 年 12 月 31 日期间,在俄亥俄州立大学综合癌症中心参加俄亥俄州大肠癌预防计划的 341 名子宫内膜癌患者入组。所有肿瘤均进行了四种 MMR 蛋白的免疫组织化学(IHC)染色、MSI 检测,如果肿瘤 MMR 缺失(dMMR),则进行 MLH1 甲基化检测。所有 dMMR 肿瘤缺乏 MLH1 甲基化的病例均进行林奇综合征种系基因检测。如果未发现种系 MMR 基因 PV,则进行肿瘤测序。
27%(91/341)的肿瘤为 MSI-高或 IHC 异常提示 dMMR。如预期的那样,大多数 dMMR 肿瘤存在 MLH1 甲基化;(69 例,占 dMMR 病例的 75.8%;占总数的 20.2%)。在 22 例(6.5%)无法用甲基化解释的 dMMR 病例中,发现 10 例(占总数的 2.9%)患有林奇综合征(6 例 MSH6、3 例 MSH2、1 例 PMS2)。其余 12 例 dMMR 病例(占总数的 3.5%)归因于双体细胞 MMR PV。
由于双体细胞 MMR 基因 PV 在子宫内膜癌患者中与林奇综合征一样常见,对于非甲基化 dMMR 肿瘤患者,进行配对肿瘤和种系检测可能是 LS 筛查的最有效方法。